Drug | Drug MOA | Development status | Disease |
RSLV132 | RNA hydrolysis | Phase II | Systemic lupus erythematosus Sjögren's syndrome |
SM101 | Anti–immune complex | Phase II | Systemic lupus erythematosus Lupus nephritis |
BIIB059 | Anti-BDCA2 (pDCs) | Phase II | Systemic lupus erythematosus |
MEDI-7734 | Anti-ILT7 (pDCs) | Phase I | Dermatomyositis Polymyositis Systemic sclerosis Sjögren's syndrome Systemic lupus erythematosus |
JNJ-55920839 | Anti–IFN-α/ω | Phase I | Systemic lupus erythematosus |
AGS-009 | Anti–IFN-α | Phase I* | Systemic lupus erythematosus |
IFN-α-kinoid | Anti–IFN-α | Phase II | Dermatomyositis |
Phase II | Systemic lupus erythematosus | ||
Anifrolumab | Anti-IFNAR1 | Phase II | Lupus nephritis |
Phase III | Systemic lupus erythematosus | ||
Baricitinib† | JAK1/JAK2 inhibitor | Phase II | Systemic lupus erythematosus |
PF-04965842 | JAK1 inhibitor | Phase II | Systemic lupus erythematosus |
*Development status unknown.
†European Medicines Agency approved for rheumatoid arthritis.
IFN, interferon; IFNAR1, type I interferon alpha receptor subunit 1; ILT7, immunoglobulin-like transcript 7; JAK, Janus kinase; MOA, mechanism of action; pDCs, plasmacytoid dendritic cell.